[go: up one dir, main page]

MX2012004118A - Metodos para prevenir o tratar sarcopenia y atrofia muscular en animales. - Google Patents

Metodos para prevenir o tratar sarcopenia y atrofia muscular en animales.

Info

Publication number
MX2012004118A
MX2012004118A MX2012004118A MX2012004118A MX2012004118A MX 2012004118 A MX2012004118 A MX 2012004118A MX 2012004118 A MX2012004118 A MX 2012004118A MX 2012004118 A MX2012004118 A MX 2012004118A MX 2012004118 A MX2012004118 A MX 2012004118A
Authority
MX
Mexico
Prior art keywords
animals
preventing
methods
muscle atrophy
treating sarcopenia
Prior art date
Application number
MX2012004118A
Other languages
English (en)
Inventor
Sunil Kochhar
Yuanlong Pan
Serge Andre Dominique Rezzi
Francoise-Pierre Martin
Emma Peretrepat
Sebastiano Collino
Francia Arce Vera
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2012004118A publication Critical patent/MX2012004118A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)

Abstract

La invención proporciona métodos para uno o más de prevenir o tratar sarcopenia y atrofia muscular en animales. Los métodos comprenden administrar isoflavonas a los animales, de preferencia en cantidades de aproximadamente 0.001 a alrededor de 10 g/kg/día.
MX2012004118A 2009-10-09 2010-10-08 Metodos para prevenir o tratar sarcopenia y atrofia muscular en animales. MX2012004118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27863309P 2009-10-09 2009-10-09
PCT/US2010/002722 WO2011043827A1 (en) 2009-10-09 2010-10-08 Methods for preventing or treating sarcopenia and muscle atrophy in animals

Publications (1)

Publication Number Publication Date
MX2012004118A true MX2012004118A (es) 2012-05-08

Family

ID=43857050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004118A MX2012004118A (es) 2009-10-09 2010-10-08 Metodos para prevenir o tratar sarcopenia y atrofia muscular en animales.

Country Status (12)

Country Link
US (1) US9301941B2 (es)
EP (1) EP2485740B1 (es)
JP (1) JP6122638B2 (es)
CN (1) CN102573857A (es)
AU (1) AU2010303872B2 (es)
BR (1) BR112012008238A2 (es)
CA (1) CA2776950C (es)
ES (1) ES2688447T3 (es)
IN (1) IN2012DN02624A (es)
MX (1) MX2012004118A (es)
RU (1) RU2558534C2 (es)
WO (1) WO2011043827A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
EP3520793B1 (en) * 2011-06-06 2023-03-29 University of Iowa Research Foundation Substances and compostions for use in methods of inhibiting muscle atrophy
WO2013058579A1 (ko) * 2011-10-18 2013-04-25 (주)아모레퍼시픽 시링가레시놀을 포함하는 sirt 1 활성화제
SG10201809153WA (en) * 2014-04-28 2018-11-29 Suntory Holdings Ltd Muscle atrophy inhibitor containing quercetin glycoside
EP3256004A1 (en) 2015-02-13 2017-12-20 Mars, Incorporated Pet food feeding system
KR20170002846A (ko) 2015-06-30 2017-01-09 (주)아모레퍼시픽 콩잎 추출물을 유효성분으로 함유하는 근질환 억제 및 예방용 조성물
GB201522304D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product for reducing muscle breakdown
GB201721627D0 (en) 2017-12-21 2018-02-07 Mars Inc Pet food product
CN108635571B (zh) * 2018-07-19 2021-10-22 西安交通大学医学院第一附属医院 鸢尾素(irisin)在制备预防及治疗重症急性胰腺炎药物中的应用
EP4039329A4 (en) * 2019-10-04 2023-08-02 Suntory Holdings Limited COMPOSITION FOR SUPPRESSING LOSS OF MUSCLE MASS, PREVENTING LOSS INSIDE, MAINTAINING, RECOVERING OR ENHANCING ITS INSIDE
KR102623198B1 (ko) * 2020-02-26 2024-01-10 한국 한의학 연구원 돌콩 추출물을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소의 예방, 개선 또는 치료용 조성물
RU2756154C1 (ru) * 2020-11-13 2021-09-28 Митхат Зульфугар-Оглы Гасанов Способ диагностики саркопении у пациентов с хронической болезнью почек 5д стадии, получающих лечение программным гемодиализом
KR102803173B1 (ko) * 2021-02-22 2025-05-07 한국 한의학 연구원 황기 추출물로부터 분리한 화합물을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생, 근감소 또는 근피로의 예방, 개선 또는 치료용 조성물
WO2023140407A1 (ko) * 2022-01-21 2023-07-27 경상국립대학교병원 쿠메스트롤을 포함하는 근감소증 예방 또는 치료용 약학 조성물
KR102803976B1 (ko) * 2022-04-06 2025-05-07 국립강릉원주대학교산학협력단 때죽나무 잎 추출물을 포함하는 근력강화용 조성물
WO2025121473A1 (ko) * 2023-12-06 2025-06-12 경상국립대학교병원 아세틸제니스틴을 포함하는 근감소증의 예방 또는 개선용 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166380B (es) * 1973-07-09 1975-03-28
US6887499B2 (en) * 2000-05-22 2005-05-03 Enitan A. Bababunmi Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
EP1192943A3 (en) * 2000-09-28 2002-11-27 Pfizer Products Inc. Use of growth hormone secretagogues in conjunction with physical exercise
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
US20070185012A1 (en) * 2003-07-10 2007-08-09 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
CA2553814A1 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Treating a viral disorder
RU2366274C2 (ru) * 2004-03-17 2009-09-10 Нестек С.А. Композиции и способы снижения или предупреждения ожирения
CN101495183A (zh) * 2006-05-24 2009-07-29 帝斯曼知识产权资产管理有限公司 治疗肌肉障碍和改善肌肉功能
CN107007581A (zh) 2006-08-24 2017-08-04 田纳西大学研究基金会 取代的n‑酰基苯胺及其使用方法

Also Published As

Publication number Publication date
IN2012DN02624A (es) 2015-05-22
EP2485740B1 (en) 2018-08-29
EP2485740A1 (en) 2012-08-15
CA2776950C (en) 2023-11-21
RU2558534C2 (ru) 2015-08-10
BR112012008238A2 (pt) 2017-06-06
AU2010303872A1 (en) 2012-04-19
ES2688447T3 (es) 2018-11-02
RU2012118686A (ru) 2013-11-20
CN102573857A (zh) 2012-07-11
EP2485740A4 (en) 2013-04-03
JP2013507361A (ja) 2013-03-04
AU2010303872B2 (en) 2016-06-23
US20120238515A1 (en) 2012-09-20
WO2011043827A1 (en) 2011-04-14
CA2776950A1 (en) 2011-04-14
US9301941B2 (en) 2016-04-05
JP6122638B2 (ja) 2017-04-26

Similar Documents

Publication Publication Date Title
MX2012004118A (es) Metodos para prevenir o tratar sarcopenia y atrofia muscular en animales.
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
JO3267B1 (ar) بيرولات [3، 4-سي] اوكتاهيدروبيرولو ثنائية الاستبدال كمعدلات لمستقبل اوريكسين
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
EA201370208A1 (ru) Формы рифаксимина и их применение
IL195030A (en) Dpp iv inhibitor formulations
CY1118062T1 (el) Συνθεσεις για την αντιμετωπιση της ναυτιας και του εμετου κεντρικης προελευσης
HRP20160598T1 (hr) Bakterijski sastavi za prevenciju i liječenje degenerativne bolesti
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
UA109123C2 (uk) Пробіотична композиція для застосування в лікуванні запалення кишечнику
IN2012DN00624A (es)
TN2011000482A1 (en) Organic compounds and their uses
GT201200038A (es) Composicion para tratar la fibrosis quistica
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
TNSN08400A1 (en) Organic compounds and their uses
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
SE0800742L (sv) Vikttäcke
EA201200428A1 (ru) Композиция и способ для лечения ожирения

Legal Events

Date Code Title Description
FG Grant or registration